These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15506350)

  • 1. [Essential hypertension and natriuretic peptides].
    Kanmatsuse K; Fujita H
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():110-2. PubMed ID: 15506350
    [No Abstract]   [Full Text] [Related]  

  • 2. The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment.
    Machowska A; Juszczak K; Novak P; Thor P
    Folia Med Cracov; 2009; 50(3-4):35-42. PubMed ID: 21853869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omapatrilat.
    Armstrong PW; Lorell BH; Nissen S; Borer J
    Circulation; 2002 Aug; 106(6):e9011-2. PubMed ID: 12187916
    [No Abstract]   [Full Text] [Related]  

  • 5. [A new class of potent antihypertensive agents. Especially systolic pressure is significantly reduced].
    MMW Fortschr Med; 1999 Nov; 141(47):8. PubMed ID: 10912157
    [No Abstract]   [Full Text] [Related]  

  • 6. Vasopeptidase inhibition: a new direction in cardiovascular treatment.
    Asher JR; Naftilan AJ
    Curr Hypertens Rep; 2000 Aug; 2(4):384-91. PubMed ID: 10981174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Robl JA; Sun CQ; Stevenson J; Ryono DE; Simpkins LM; Cimarusti MP; Dejneka T; Slusarchyk WA; Chao S; Stratton L; Misra RN; Bednarz MS; Asaad MM; Cheung HS; Abboa-Offei BE; Smith PL; Mathers PD; Fox M; Schaeffer TR; Seymour AA; Trippodo NC
    J Med Chem; 1997 May; 40(11):1570-7. PubMed ID: 9171867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vasopeptidase inhibition: a new mechanism of action--a new antihypertensive drug].
    Waeber B
    Praxis (Bern 1994); 2000 Apr; 89(16):649-53. PubMed ID: 10823018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
    Trindade PT; Rouleau JL
    Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Omapatrilat--new drug for patients with hypertension and heart failure].
    Dzielska-Olczak M
    Pol Merkur Lekarski; 2005 Oct; 19(112):556-8. PubMed ID: 16379325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
    Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
    Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vasopeptidase inhibition. A new mechanism of action for the treatment of hypertension and cardiac insufficiency].
    Kolloch R; Offers E
    Internist (Berl); 2001 Feb; 42(2):290-6. PubMed ID: 11244883
    [No Abstract]   [Full Text] [Related]  

  • 13. [Vasopeptidase inhibitors: new pharmacologic classes, new therapeutic opportunities].
    Morganti A
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 2):829-31. PubMed ID: 12497830
    [No Abstract]   [Full Text] [Related]  

  • 14. [Progress on the drug therapy for diabetic microangiopathies: RA system inhibitor].
    Higashiura K; Shimamoto K
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():144-9. PubMed ID: 15999698
    [No Abstract]   [Full Text] [Related]  

  • 15. [Role of natriuretic peptides in blood pressure regulation].
    Hirata Y
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():56-9. PubMed ID: 15506337
    [No Abstract]   [Full Text] [Related]  

  • 16. More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2).
    Lip GY; Beevers DG
    J Hum Hypertens; 2003 Nov; 17(11):747-50. PubMed ID: 14578913
    [No Abstract]   [Full Text] [Related]  

  • 17. [Current aspects of tissue renin-angiotensin systems: atrial natriuretic peptide and prostaglandins in arterial hypertension].
    Ferreira Montero IJ
    Rev Esp Cardiol; 1990; 43 Suppl 1():24-33. PubMed ID: 2139975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of stress and behavioral interventions in hypertension: the rise and fall of omapatrilat.
    Pickering TG
    J Clin Hypertens (Greenwich); 2002; 4(5):371-3. PubMed ID: 12368583
    [No Abstract]   [Full Text] [Related]  

  • 19. [Omapatrilat for treatment of heart failure].
    Yamazaki T
    Nihon Rinsho; 2007 May; 65 Suppl 5():173-5. PubMed ID: 17571381
    [No Abstract]   [Full Text] [Related]  

  • 20. [Vasopeptidase inhibition: a new pharmacological principle in the treatment of hypertension and cardiac insufficiency].
    Kolloch R; Offers E
    Dtsch Med Wochenschr; 2001 Nov; 126(47):1342-7. PubMed ID: 11719860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.